Bullish option flow detected in Biogen (BIIB) with 2,556 calls trading, 1.5x expected, and implied vol increasing over 1 point to 34.69%.

Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that ...

Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYStm (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 years of age and older.2 This ...

Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

People who are 75 and older will compose 10% of the total population in the U.S. by 2030, representing a 7.5% increase from ...

TD Cowen analyst Phil Nadeau maintained a Hold rating on Xoma (XOMA – Research Report) yesterday. The company’s shares closed yesterday at ...

Experts at the 2025 Clinical Trial Supply New England conference will discuss strategies for optimising clinical supply chains.

Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYS™ (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 years of age and older.2 This approval ...

A bill that could help Illinois residents access Alzheimer’s treatment is making its way through the House. House Bill 1360 ...

The global leukemia therapeutics treatment market is expected to grow at a CAGR of 6.6% during the forecast period (2025–2035). Factors such as the rising prevalence of leukemia, increasing adoption ...

Wall Street was poised to open slightly lower after U.S. President Donald Trump told reporters he was pushing forward with ...